Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441255 in lean to overweight adults
NCT04521738Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SAR441255 with Placebo (2 arms). Primary endpoint: Adverse Events at 28 days. Started Apr 2019; status: completed.
02
Drugs
SAR441255
Beyond the preview
Go deeper on NCT04521738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521738.